PEACCEL and SYNTHELIS have signed a strategic partnership to increase the chances of success of your drugs
12 May 2022
PEACCEL and SYNTHELIS have signed a strategic partnership to offer their clients and partners a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.
Read more..
PEACCEL has just received the award “Life Sciences AI company of the Year” from CorporateLiveWire !
27 August 2021
PEACCEL listed in The Digest of Global AI in Pharma Investment
4 August 2021
PEACCEL is listed in The Digest of Global AI in Pharma Investment.https://www.linkedin.com/posts/alina-timoshenkova-5b0a6364_top-countries-in-ai-for-drug-discovery-sector-activity-6828674970089078784-xobr/
PEACCEL mentioned as a AI start-up to watch by NVIDIA
6 April 2021
PEACCEL mentioned as a AI start-up to watch by NVIDIA.Three Trends for Healthcare AI Startups To Watch Renee Y. | 19 mars 2021
https://www.linkedin.com/pulse/three-trends-healthcare-ai-startups-watch-renee-yao
PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021: Market report by Cision (NYSE: CISN).
6 April 2021
PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021: Market report by Cision (NYSE: CISN).
PEACCEL awarded by Wealth & Finance
15 February 2021
PEACCEL has just received two Artificial Intelligence Awards from Wealth & Finance :
– Best Drug Development AI Partner 2020
– Most Innovative Clinical Data Science Platform : innov’SAR